ClinicalTrials.gg
RecruitingNCT07653347IRISUpdated Jun 17, 2026

Infant RSV Immunity Study

An observational study in Respiratory Synctial Virus and Asthma Childhood, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged Up to 6 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by University of British Columbia · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
Up to 6 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Asthma by University of British Columbia — 5 open to participants now, 5 under way, none of them phase 3. Asthma · University of British Columbia.

Started
2026
with 1 other
Observational
6 of 20
2 open now
Registered
20th of 20
by date

Among the 20 studies in Asthma by University of British Columbia, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 20th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 20 studies in Asthma by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: Up to 6 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Asthma by University of British Columbia, or all of them as a file.
02

Study summary

Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\<4 months) versus late (>6-9 months) in infancy.

Read the detailed description

In British Columbia (Canada), RSV cases rise each year after mid-October, until April, peaking in December. This study compares outcomes between infants born in April to June, who will be naturally exposed to RSV >6-9 months of age versus infants born in September to November, who will be naturally exposed to RSV \<4 months of age. Most infants become infected during their first RSV year.

Primary Objectives:

  1. Compare post-season RSV immune responses between the spring cohort of infants born in April to June versus the fall cohort of infants born in September to November.
  2. Compare respiratory outcomes at 3 years of age between the spring cohort of infants born in April to June versus the fall cohort of infants born in September to November.

Secondary Objectives:

  1. Identify immune maturation events linked to stronger post-season RSV antibody responses.
  2. Determine how the gut and upper airway microbiota co-evolve in infants over the first year of life, and how these dynamics shape RSV risk, and are shaped by host-related, and specifically seasonal factors (i.e. Apr-Jun versus Sept-Nov).
  3. Compare immune responses during acute RSV infections between the spring cohort of infants born in April to June versus the fall cohort of infants born in September to November.

Design:

Prospective, observational cohort study of 300 parent-infant pairs born in the spring (April-June) or fall (Sept-Nov), with follow-up at 3 years of age.

Recruitment and Informed Consent Procedure:

Birthing parents planning to give birth at the BC Women's Hospital or live locally in greater Vancouver are identified through the BC Women's Hospital prenatal ultrasound clinic or social media and contacted by the study coordinator in person, by telephone or by text message. Interested participants complete an online eligibility questionnaire and, if eligible, the online consent form. Study advertisements posted in the hospital, local clinics, local community centers and on social media direct interested parents to the study website, online eligibility questionnaire and the study coordinators contact information.

Patients who delivered an infant during the study eligibility period in the Vancouver Coastal Health region are also invited by mail and enrolled prior to the start of the respiratory season for the spring cohort (September/October 2026) or prior to the post-season study visit for the fall cohort (May/June 2027).

Written informed consent is obtained from all participants prior to study procedures. The study has been approved by the University of British Columbia Children's and Women's Research Ethics Board (H25-02623).

Study Procedures:

At enrollment, parents are asked to complete a baseline questionnaire that collects basic pregnancy information (e.g. maternal age, pregnancy conditions, number of babies in pregnancy), intention to receive or receipt of RSV maternal vaccine, household size / number of siblings at home and their ages, smoking, family history of asthma/use of inhalers, use of antibiotics during pregnancy, family history of atopy / asthma, presence of furry pets in the home.

In each post-season questionnaire, parents are also additionally asked about socioeconomic factors, travel, daycare use, child medication use, child hospitalization or medical visit for a respiratory infection and if their child experienced asthma or wheezing symptoms. Study staff review hospital charts at birth and each year after the respiratory season to gather information about RSV-related hospitalizations and RSV testing.

Parents complete a child feeding questionnaire at 3, 6 and 12 months to collect information on infant/child dietary intake including breastfeeding and formula use (start/end dates, duration) and introduction of solid foods.

Biospecimen Collection:

A cord blood sample collected at delivery. If cord blood cannot be collected, a peripheral blood sample is taken at a scheduled study visit within one month after birth, at BC Children's Hospital. If enrolled greater than 1 month after delivery, cord/peripheral blood is not collected. To account for pre-season RSV antibody levels in the analysis, an additional pre-season dried blood spot (DBS) sample are collected in September from the spring cohort babies. We also obtain a residual sample from the Newborn Screening DBS at birth in all infants, for measurements of RSV antibody levels and neutralization titers.

A post-season blood sample is collected from all participants at a scheduled study visit at BC Children's Hospital in May or June following the RSV season.

Serology samples are used to quantify RSV antibodies and neutralization titers, and RSV F-specific antibody-dependent function.

Cord blood and peripheral blood mononuclear cells are stored from the cord and post-natal blood samples, to measure RSV T and B cell responses. A sample is also stored for whole blood RNA-Sequencing studies (PAXgene).

Prenatal and delivery serology samples are obtained from routine samples collected from birthing parents. An additional maternal blood sample is collected at the scheduled post-season study visit in May or June 2027.

RSV Testing and Respiratory Outcome Questionnaires:

Infants are monitored for respiratory outcomes (wheezing episodes) throughout each RSV season (September to March) using parent-completed diaries and parent-collected nasal swab testing when child exhibit pre-defined symptom criteria for infection (e.g. fever, cough, nasal congestion, difficulty breathing).

A subset of infants who test positive for RSV during the acute illness are invited to provide a blood sample about 2 weeks into the acute illness.

Diaries will be used for parents to record each episode of a respiratory infection, the severity and duration of the episode, and to track wheezing days.

Microbiome Studies:

A subset of at least 50 birthing parents in each (Apri-Jun / Sept/Nov) group provide a self-collected vaginal swab within 2 weeks after birth.

Oral swabs are collected from the infants around 2 weeks of age. In addition, stool samples are collected on children at 3, 6, 9 and 12 months of age. For children recruited greater than 1 month after delivery, microbiome samples are not collected.

Main Outcomes:

The study sample size is determined based on the respiratory outcome at 3 years, using the Child Healthy Infant Longitudinal Development study has developed and validated the (CHILDhood Asthma Risk Tool) CHART tool.

The main post-season outcomes are RSV antibody levels and neutralization, with main comparisons between the spring and fall groups/cohorts.

03

Conditions studied

  • Respiratory Synctial Virus
  • Asthma Childhood

Browse trials for

Keywords

  • cohort study
  • Immune response
  • infants
  • season of birth
04

Who can participate

Ages eligible
Up to 6 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Birthing parents who have a due date or delivery date in April, May or June 2026 (spring group/cohort) or September, October or November 2026 (fall group/cohort) with follow-up of the birthing parent and child during the 2026-2027, 2027-2028 and 2028-2029 RSV seasons. Children will be followed up to 3 years of age. The cohort will consist of 300 birthing parent-child pairs, with 150 in the spring cohort and 150 in the fall cohort. Birthing parents are recruited during antenatal care or shortly after delivery from the ultrasound clinic or delivery wards at BC Women's Hospital, patient lists from local maternity wards within the Vancouver Coastal Health Authority or advertisements at local prenatal care centres (obstetrician, physician and midwife clinics), community centres or on social media.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Birthing parent/child pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital.

Exclusion criteria

Exclusion Criteria:

Severe pregnancy-related complications or chronic medical conditions in the children making them automatically eligible to receiving RSV immunoprophylaxis in British Columbia (e.g. infants born prematurely \< 35 weeks of gestation, or with chronic medical conditions).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Fall group/cohort

    Infants exposed to RSV \<4 months of age (born September-November)

  • Spring group/cohort

    Infants exposed to RSV \>6-9 months of age (born April-June)

06

What researchers measure

Primary outcomes

  1. RSV antibody response

    i) RSV neutralization titers (expressed as dilution titer to prevent 95% neutralization in vitro; NT95) ii) RSV F-specific antibody-mediated complement activation iii) RSV F-specific antibody-mediated phagocytosis

    Time frame: Post-respiratory season 2027 (May 2027)

  2. Asthma symptoms

    Children will be categorized as having low, moderate or high risk of asthma based on asthma-like symptoms defined using the Childhood Asthma Risk Tool (CHART)

    Time frame: at age 3 years old

Secondary outcomes

  1. Medically attended RSV infections

    Incidence of RSV and Lower Respiratory Tract Infection hospitalizations and medically attended RSV infections

    Time frame: At 1 year and 3 years of age

  2. Wheezing

    Proportion of infants who develop persistent wheezing after their first RSV episode, and the number of wheezing days during season, and after each episode of RSV infection.

    Time frame: During first RSV season (Sept to April), and each season, up to 3 years of age (for number of wheezing days during season).

Other outcomes

  1. Gut and upper airway microbiota

    Characterization of gut and upper airway microbiota, with quantification of within- (α-diversity; Shannon index) and between-sample (β-diversity; Bray-Curtis or UniFrac) diversity.

    Time frame: 0, 3, 6, 9 and 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Pending approval by our local Research Ethics Board.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 16 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jun 17, 2026
StartActual
Jan 15, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Dec 1, 2029
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07653347
Responsible party
Pascal Lavoie (Professor and Neonatologist, University of British Columbia) — Principal investigator
First posted
Jun 17, 2026
Start date
Jan 15, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Jun 17, 2026

Study contacts

Pascal Lavoie, MDCM PhD FRCPC
Contact
plavoie@bcchr.ca
604-875-2135
Allison Watts, PhD
Contact
awatts@bcchr.ca
604-875-2000 ext. 6705

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion